Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients - The Lancet Oncology
The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score - Yang - 2023 - Cancer Medicine - Wiley Online Library
Breast cancer-specific survival by body mass index categories for... | Download Scientific Diagram
Frontiers | High Parity Predicts Poor Outcomes in Patients With Luminal B-Like (HER2 Negative) Early Breast Cancer: A Prospective Finnish Single-Center Study
Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives | Journal of Clinical Oncology
Disease-free survival curves of luminal type A and B breast cancer. | Download Scientific Diagram
Relapse-free survival in luminal A-like versus luminal B-like breast... | Download Scientific Diagram
Prognosis of Tumor Microenvironment in Luminal B-Type Breast Cancer
IJMS | Free Full-Text | How to Predict Metastasis in Luminal Breast Cancer? Current Solutions and Future Prospects
Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes - Sereda - Translational Breast Cancer Research
:max_bytes(150000):strip_icc()/GettyImages-1389278061-ca025a5867e04ce18d7fc1b2ecba8ce2.jpg "Luminal B Breast Cancer: Symptoms, Diagnosis, and More")
Luminal B Breast Cancer: Symptoms, Diagnosis, and More
Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes – an observational cohort study in Sweden | BMC Cancer | Full Text
Breast Cancer Subtypes And Prognosis | BCTT
Basal-like carcinoma - Wikipedia
Overall survival depends on tumor subtype and systemic treatment. a... | Download Scientific Diagram
Biomedicines | Free Full-Text | Association between Obesity, Race or Ethnicity, and Luminal Subtypes of Breast Cancer
Luminal B Breast Cancer: Symptoms, Diagnosis, and Treatment
Luminal B Breast Cancer: Symptoms, Diagnosis, and Treatment
Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors
Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes - Sereda - Translational Breast Cancer Research
Triple negative breast cancer therapies nanomedicine - Inside Tx
The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer | npj Breast Cancer
